Dermmedica Sp. z o.o. — Clinical Trial Site

56 Registered trials

19 Currently recruiting

Organisation

Dermmedica Sp. z o.o.

Location

Wroclaw, Poland

Identifier

ORG-100044147

Address

Ul. Zakrzowska 19a, 51-318, Poland

Departments

#40333: Dermatology
#40738: DermMedica Sp. z o.o.
#40773; Clinical Trials Department
40333: NAP
40862: Dermatology
503: Centrum Columbus
Centrum Columbus
Dermatology
Dermatology and Venerology
Dermatology Department
DermMedica
DermMEDICA Sp. z o.o.
Dermmedica Sp. z o.o., Centrum Columbus
N/A
NA
not applicable/nie dotyczy
PL10022: Rheumatology

Clinical trials at this site (56)

Search interface

A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label E… Ended

2022-502827-23-00 Chronic Hand Eczema 4 2023-10-12
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Hidradenitis Suppurativa 5 2023-06-15
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Atopic Dermatitis 5 2023-05-23
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15
A study to learn how safe bimekizumab, how well it works and how it moves through the bloodstream in adolescents with moderate to severe pla… Ended

2023-509832-24-00 Moderate to Severe Plaque Psoriasis 4 2021-08-30
An extension study to learn if Bimekizumab is safe and works as a long-term therapy in adults with moderate to severe hidradenitis suppurati… Ended

2024-511035-10-00 Hidradenitis Suppurativa 5 2021-06-23
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12